If there is one discipline in the clinic which will profitfrom the recent major advances made in gene modificationtechnologies, it must be hematology, sincemany hematological disorders are based on welldescribed aberrations in the human genome. In thisreview we describe CRISPR/Cas and the inroads it ismaking in hematology-based research; developmentswhich might lead to gene therapy.
|Translated title of the contribution||CRISPR/Cas-mediated gene editing and the potential application in hematological disease|
|Journal||Nederlands Tijdschrift voor Hematologie|
|Publication status||Published - Jan 2017|